Loading...
Docoh

Seelos Therapeutics (SEEL)

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.

Company profile

SEEL stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Aug 22
18 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 41.25M 41.25M 41.25M 41.25M 41.25M 41.25M
Cash burn (monthly) 6.84M 3.83M 7.08M 6.13M 6.8M 5.52M
Cash used (since last report) 11.26M 6.31M 11.66M 10.09M 11.2M 9.1M
Cash remaining 29.99M 34.95M 29.59M 31.16M 30.06M 32.15M
Runway (months of cash) 4.4 9.1 4.2 5.1 4.4 5.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jun 22 O'Connor Daniel J. Common Stock Buy Acquire P No No 0.6118 16,000 9.79K 16,000
26 May 22 Dalesandro Margaret Common Stock Buy Acquire P No No 0.599 35,000 20.97K 35,000
31 Mar 22 Mehra Raj Common Stock Buy Acquire P No No 0.8526 66,667 56.84K 3,281,546
28 Feb 22 Michael Joseph Golembiewski Common Stock Grant Acquire A No No 0.901 12,500 11.26K 78,487
10 Jan 22 Michael Joseph Golembiewski Stock Option Common Stock Grant Acquire A No No 1.46 500,000 730K 500,000
39.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 92 102 -9.8%
Opened positions 12 13 -7.7%
Closed positions 22 23 -4.3%
Increased positions 26 37 -29.7%
Reduced positions 28 23 +21.7%
13F shares Current Prev Q Change
Total value 37.34M 106.05M -64.8%
Total shares 41.64M 43.12M -3.4%
Total puts 123.1K 100.1K +23.0%
Total calls 702.3K 2.55M -72.5%
Total put/call ratio 0.2 0.0 +347.0%
Largest owners Shares Value Change
BLK Blackrock 6.29M $5.27M -4.1%
Vanguard 5.65M $4.74M +9.8%
Gendell Jeffrey L 4.93M $4.13M +101.4%
Woodline Partners 2.8M $2.35M -30.7%
Group One Trading 2.24M $1.88M +131.0%
LGND Ligand Pharmaceuticals 2.22M $3.51M 0.0%
Mirae Asset Global Investments 1.93M $1.62M +36.5%
STT State Street 1.75M $1.46M +5.1%
Renaissance Technologies 1.72M $1.44M NEW
Geode Capital Management 1.62M $1.36M +2.1%
Largest transactions Shares Bought/sold Change
Gendell Jeffrey L 4.93M +2.48M +101.4%
Acuta Capital Partners 295.9K -2.2M -88.2%
Mangrove Partners 0 -2.13M EXIT
Renaissance Technologies 1.72M +1.72M NEW
Group One Trading 2.24M +1.27M +131.0%
Woodline Partners 2.8M -1.24M -30.7%
Norges Bank 0 -783.8K EXIT
Millennium Management 216.01K -542.29K -71.5%
Mirae Asset Global Investments 1.93M +517.52K +36.5%
Vanguard 5.65M +504.51K +9.8%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: affixed, AgreementSM, arrive, Australia, basket, caution, circulate, clarify, covenant, effectuating, Huntington, indefinite, indemnification, preliminary, promulgated, pronouncement, split, verification
Removed: recognizing, startup